JY
GLUE icon

Jeff Yass’s Monte Rosa Therapeutics GLUE Stock Holding History

Jeff Yass’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$830K Buy
34,281
+9,530
+39% +$180K ﹤0.01% 8680
2026
Q1 		$407K Buy
24,751
+13,844
+127% +$265K ﹤0.01% 10164
2025
Q4 		$171K Sell
10,907
-5,279
-33% -$71.1K ﹤0.01% 11042
2025
Q3 		$120K Sell
16,186
-43,164
-73% -$229K ﹤0.01% 11451
2025
Q2 		$268K Buy
59,350
+6,012
+11% +$26.8K ﹤0.01% 10598
2025
Q1 		$247K Buy
53,338
+32,816
+160% +$201K ﹤0.01% 10494
2024
Q4 		$142K Buy
+20,522
New +$154K ﹤0.01% 11061
2024
Q1 		– Sell
-46,387
Closed -$275K – 12596
2023
Q4 		$262K Buy
+46,387
New +$182K ﹤0.01% 10115
2023
Q2 		– Sell
-13,111
Closed -$84.8K – 12458
2023
Q1 		$102K Buy
+13,111
New +$91.2K ﹤0.01% 11279
2022
Q4 		– Sell
-18,916
Closed -$158K – 12869
2022
Q3 		$155K Sell
18,916
-7,498
-28% -$68.9K ﹤0.01% 11188
2022
Q2 		$255K Buy
+26,414
New +$265K ﹤0.01% 9997

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's GLUE Position: Q2 2026 in Review

Jeff Yass increased its Monte Rosa Therapeutics (GLUE) stake by 39% in Q2 2026, buying an estimated $180K and bringing the position to 34,281 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #8680.

Jeff Yass first reported a position in GLUE in Q2 2022 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Jeff Yass held 34,281 shares of Monte Rosa Therapeutics worth $830K as of Q2 2026.
  • Jeff Yass bought 9,530 Monte Rosa Therapeutics shares in Q2 2026, an estimated $180K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8680 holding.
  • Jeff Yass first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.